Athenex, Inc. (NASDAQ:ATNX) Short Interest Update

Athenex, Inc. (NASDAQ:ATNX – Get Rating) was the recipient of a significant decline in short interest in the month of April. As of April 30th, there was short interest totalling 356,300 shares, a decline of 9.9% from the April 15th total of 395,500 shares. Based on an average daily volume of 102,500 shares, the short-interest ratio is currently 3.5 days. Currently, 4.7% of the company’s shares are short sold.

Hedge Funds Weigh In On Athenex

Hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC boosted its stake in shares of Athenex by 34.1% in the first quarter. Renaissance Technologies LLC now owns 1,222,239 shares of the company’s stock valued at $1,014,000 after purchasing an additional 310,539 shares during the period. UBS Group AG increased its stake in shares of Athenex by 4.3% during the first quarter. UBS Group AG now owns 551,810 shares of the company’s stock worth $458,000 after buying an additional 22,819 shares during the period. Mirabella Financial Services LLP purchased a new position in Athenex in the first quarter worth approximately $37,000. Millennium Management LLC grew its stake in shares of Athenex by 104.1% during the second quarter. Millennium Management LLC now owns 4,578,195 shares of the company’s stock worth $1,874,000 after purchasing an additional 2,335,225 shares in the last quarter. Finally, Citadel Advisors LLC increased its holdings in shares of Athenex by 844.4% in the 2nd quarter. Citadel Advisors LLC now owns 585,191 shares of the company’s stock valued at $240,000 after acquiring an additional 523,228 shares during the last quarter. 30.48% of the stock is owned by hedge funds and other institutional investors.

Athenex Price Performance

NASDAQ:ATNX opened at $0.38 on Wednesday. The firm has a market cap of $3.29 million, a price-to-earnings ratio of -0.02 and a beta of 1.36. The company has a 50 day moving average price of $1.35 and a 200-day moving average price of $0.88. The company has a debt-to-equity ratio of 3.08, a current ratio of 1.09 and a quick ratio of 0.72. Athenex has a 1-year low of $0.35 and a 1-year high of $23.80.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH downgraded shares of Athenex from a “buy” rating to a “neutral” rating in a research note on Tuesday, March 21st.

Athenex Company Profile

(Get Rating)

Athenex, Inc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs.